Prognostic factors in patients with stage II colon cancer: Role of E-selectin gene polymorphisms.

[1]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[2]  D. Vernerey,et al.  Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments. , 2018, European journal of cancer.

[3]  O. Margalit,et al.  Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. , 2018, European journal of cancer.

[4]  F. dall’Olio,et al.  Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers , 2017, Biology.

[5]  J. Kamińska,et al.  Lectin adhesion proteins (P-, L- and E-selectins) as biomarkers in colorectal cancer , 2016, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[6]  R. Strausberg,et al.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.

[7]  R. Labianca,et al.  Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  F. Guadagni,et al.  Serum sE‐selectin levels and carcinoembryonic antigen mRNA‐expressing cells in peripheral blood as prognostic factors in colorectal cancer patients , 2010, Cancer.

[9]  S. Truant,et al.  E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer. , 2009, European journal of cancer.

[10]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Konstantopoulos,et al.  Carcinoembryonic Antigen and CD44 Variant Isoforms Cooperate to Mediate Colon Carcinoma Cell Adhesion to E- and L-selectin in Shear Flow* , 2008, Journal of Biological Chemistry.

[12]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[13]  D. Nance,et al.  Interactions between cancer cells and the endothelium in metastasis , 2000, The Journal of pathology.

[14]  Y. Chung,et al.  Increased sialyl Lewis A expression and fucosyltransferase activity with acquisition of a high metastatic capacity in a colon cancer cell line. , 1997, British Journal of Cancer.

[15]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[16]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .